Publikation: Human lung carcinomas express Fas ligand
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
To reach a clinically detectable size, neoplasms must be able to suppress or evade a host immune response. Activated T cells may enter apoptosis in the presence of Fas ligand (FasL) (1), and tissue expression of FasL has been shown to contribute to immune privilege in the eye and testis (2, 3). We have demonstrated that all human lung carcinoma cell lines tested (16 of 16) express a Mr 38,000 protein consistent with FasL by immunoblotting, whereas the majority of resected tumors (23 of 28) show positive staining for FasL by immunohistochemistry. DNA sequencing of reverse transcription-PCR products from lung cancer cells and resected lung tumors confirms the presence of human FasL mRNA in these neoplastic tissues. Furthermore, lung carcinoma cells are capable of killing a Fassensitive human T cell line (Jurkat) in coculture experiments; this killing was inhibited by a recombinant form of the soluble portion of the Fas receptor (FasFc). FasL expression by neoplastic cells represents a potential mechanism for peripheral deletion of tumor-reactive T-cell clones.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
NIEHANS, Gloria A., Thomas BRUNNER, Sandra P. FRIZELLE, Jacob C. LISTON, Christopher T. SALERNO, Dennis J. KNAPP, Douglas R. GREEN, Robert A. KRATZKE, 1997. Human lung carcinomas express Fas ligand. In: Cancer Research. 1997, 57(6), pp. 1007-1012BibTex
@article{Niehans1997Human-14312, year={1997}, title={Human lung carcinomas express Fas ligand}, number={6}, volume={57}, journal={Cancer Research}, pages={1007--1012}, author={Niehans, Gloria A. and Brunner, Thomas and Frizelle, Sandra P. and Liston, Jacob C. and Salerno, Christopher T. and Knapp, Dennis J. and Green, Douglas R. and Kratzke, Robert A.} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/14312"> <dc:creator>Liston, Jacob C.</dc:creator> <dc:contributor>Salerno, Christopher T.</dc:contributor> <dc:creator>Frizelle, Sandra P.</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-07-29T09:06:42Z</dcterms:available> <dc:rights>terms-of-use</dc:rights> <dc:contributor>Frizelle, Sandra P.</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-07-29T09:06:42Z</dc:date> <dc:contributor>Knapp, Dennis J.</dc:contributor> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/14312"/> <dc:creator>Salerno, Christopher T.</dc:creator> <dc:creator>Green, Douglas R.</dc:creator> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dc:creator>Brunner, Thomas</dc:creator> <dc:contributor>Green, Douglas R.</dc:contributor> <dc:contributor>Niehans, Gloria A.</dc:contributor> <dc:contributor>Liston, Jacob C.</dc:contributor> <dc:creator>Niehans, Gloria A.</dc:creator> <dc:contributor>Brunner, Thomas</dc:contributor> <dc:language>eng</dc:language> <dcterms:title>Human lung carcinomas express Fas ligand</dcterms:title> <dcterms:abstract xml:lang="eng">To reach a clinically detectable size, neoplasms must be able to suppress or evade a host immune response. Activated T cells may enter apoptosis in the presence of Fas ligand (FasL) (1), and tissue expression of FasL has been shown to contribute to immune privilege in the eye and testis (2, 3). We have demonstrated that all human lung carcinoma cell lines tested (16 of 16) express a Mr 38,000 protein consistent with FasL by immunoblotting, whereas the majority of resected tumors (23 of 28) show positive staining for FasL by immunohistochemistry. DNA sequencing of reverse transcription-PCR products from lung cancer cells and resected lung tumors confirms the presence of human FasL mRNA in these neoplastic tissues. Furthermore, lung carcinoma cells are capable of killing a Fassensitive human T cell line (Jurkat) in coculture experiments; this killing was inhibited by a recombinant form of the soluble portion of the Fas receptor (FasFc). FasL expression by neoplastic cells represents a potential mechanism for peripheral deletion of tumor-reactive T-cell clones.</dcterms:abstract> <dc:creator>Kratzke, Robert A.</dc:creator> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/14312/2/1997_Niehans_Human%20Lung%20Carci.pdf"/> <dc:creator>Knapp, Dennis J.</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:issued>1997</dcterms:issued> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/14312/2/1997_Niehans_Human%20Lung%20Carci.pdf"/> <dc:contributor>Kratzke, Robert A.</dc:contributor> <dcterms:bibliographicCitation>First publ. in: Cancer Research ; 57 (1997), 6. - pp. 1007-1012</dcterms:bibliographicCitation> </rdf:Description> </rdf:RDF>